130 related articles for article (PubMed ID: 36749114)
1. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
Ingen-Housz-Oro S; Milpied B; Bensaid B; Elshot Y; Brüggen MC; Starace M; Kaffenberger BH; Carrera C; Pham-Ledard A; Freites-Martinez A; Sanchez-Pena P; Lebrun-Vignes B; French LE; Sibaud V
Melanoma Res; 2023 Apr; 33(2):155-158. PubMed ID: 36749114
[TBL] [Abstract][Full Text] [Related]
2. Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.
Maximova N; Maestro A; Zanon D; Marcuzzi A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066648
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-associated DRESS in a genetic susceptible individual.
Ai L; Gao J; Zhao S; Li Q; Cui YH; Liu Q; Wu D; Wang Y; Jin X; Ji Y; Li J; Yu Y; Liu T
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599025
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review.
Maloney NJ; Rana J; Yang JJ; Zaba LC; Kwong BY
Support Care Cancer; 2022 Mar; 30(3):2839-2851. PubMed ID: 34546454
[TBL] [Abstract][Full Text] [Related]
5. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.
Ingen-Housz-Oro S; Milpied B; Badrignans M; Carrera C; Elshot YS; Bensaid B; Segura S; Apalla Z; Markova A; Staumont-Sallé D; Marti-Marti I; Giavedoni P; Chua SL; Darrigade AS; Dezoteux F; Starace M; Torre AC; Riganti J; de Prost N; Lebrun-Vignes B; Bauvin O; Walsh S; Ortonne N; French LE; Sibaud V
Melanoma Res; 2022 Jun; 32(3):205-210. PubMed ID: 35377864
[TBL] [Abstract][Full Text] [Related]
6. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study.
Del Pozzo-Magaña BR; Rieder MJ; Garcia-Bournissen F; Lazo-Langner A
Br J Clin Pharmacol; 2022 Sep; 88(9):4134-4141. PubMed ID: 35421262
[TBL] [Abstract][Full Text] [Related]
9. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
11. Clinical features, treatment outcomes and prognostic factors of allopurinol-induced DRESS in 52 patients.
Liu Q; Zhao S; Chen W
J Clin Pharm Ther; 2022 Sep; 47(9):1368-1378. PubMed ID: 35971667
[TBL] [Abstract][Full Text] [Related]
12. Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases.
Brin C; Bernigaud C; Hua C; Duong TA; Gaudin O; Colin A; de Prost N; Wolkenstein P; Chosidow O; Ingen-Housz-Oro S
Ann Dermatol Venereol; 2021 Sep; 148(3):168-171. PubMed ID: 33858692
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic management of DRESS: a retrospective study of 38 cases.
Funck-Brentano E; Duong TA; Bouvresse S; Bagot M; Wolkenstein P; Roujeau JC; Chosidow O; Valeyrie-Allanore L
J Am Acad Dermatol; 2015 Feb; 72(2):246-52. PubMed ID: 25592341
[TBL] [Abstract][Full Text] [Related]
16. An investigation into the avoidability of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
Danjuma MI; Naseralallah LMA; AbouJabal B; Mohamed MF; Abubeker IY; Jabbar LA; Elzouki A
Sci Rep; 2021 Sep; 11(1):17887. PubMed ID: 34504198
[TBL] [Abstract][Full Text] [Related]
17. Drug reaction with eosinophilia and systemic symptoms: A single center descriptive observational study.
Sandhu S; Neema S; Vashisht D; Venugopal R; Sengupta P; Radhakrishnan S
Dermatol Ther; 2021 Jan; 34(1):e14670. PubMed ID: 33314590
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of add-on therapy with intravenous immunoglobulin in steroid hyporesponsive DRESS syndrome.
Sim DW; Yu J; Koh YI
Clin Transl Sci; 2022 Mar; 15(3):782-788. PubMed ID: 34796665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
